NES ZIONA, Israel, Feb. 17, 2026 /PRNewswire/ -- Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced that long-term data from its Phase 2 trial in moderate-to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results